Jemma Hopewell

Home / Investigators  / Jemma Hopewell

Jemma Hopewell

Associate Professor & Senior Scientist, Genetic Epidemiology and Clinical Trials, University of Oxford

Email: jemma.hopewell@ndph.ox.ac.uk
Phone: +44 (0)1865 743661

Dr. Jemma Hopewell leads a team of genetic epidemiologists, clinical fellows, medical statisticians and bioinformaticians in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a). Jemma leads and collaborates on numerous projects involving CTSU’s vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.

Recent Publications

  • Valdes-Marquez, E, Clarke, R, Hill, M, Watkins, H, Hopewell, JC. Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction. Eur J Prev Cardiol. 2023;30 (7):583-591. doi: 10.1093/eurjpc/zwad020. PubMed PMID:36702559 .
  • Clarke, R, Von Ende, A, Schmidt, LE, Yin, X, Hill, M, Hughes, AD et al.. Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease. Circ Res. 2023;132 (4):452-464. doi: 10.1161/CIRCRESAHA.122.321690. PubMed PMID:36691918 PubMed Central PMC9930889.
  • Aragam, KG, Jiang, T, Goel, A, Kanoni, S, Wolford, BN, Atri, DS et al.. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54 (12):1803-1815. doi: 10.1038/s41588-022-01233-6. PubMed PMID:36474045 PubMed Central PMC9729111.
  • Mishra, A, Malik, R, Hachiya, T, Jürgenson, T, Namba, S, Posner, DC et al.. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022;612 (7938):E7. doi: 10.1038/s41586-022-05492-5. PubMed PMID:36376532 PubMed Central PMC9712088.
  • Mishra, A, Malik, R, Hachiya, T, Jürgenson, T, Namba, S, Posner, DC et al.. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022;611 (7934):115-123. doi: 10.1038/s41586-022-05165-3. PubMed PMID:36180795 PubMed Central PMC9524349.
  • Staplin, N, Herrington, WG, Murgia, F, Ibrahim, M, Bull, KR, Judge, PK et al.. Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology. Hypertension. 2022;79 (12):2671-2681. doi: 10.1161/HYPERTENSIONAHA.122.19354. PubMed PMID:36082669 PubMed Central PMC9640248.
  • Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400 (10355):832-845. doi: 10.1016/S0140-6736(22)01545-8. PubMed PMID:36049498 PubMed Central PMC7613583.
  • Clarke, R, Hammami, I, Sherliker, P, Valdes-Marquez, E, Watkins, H, Hill, M et al.. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. Atherosclerosis. 2022;354 :15-22. doi: 10.1016/j.atherosclerosis.2022.06.1020. PubMed PMID:35803063 .
  • Linden, AB, Clarke, R, Hammami, I, Hopewell, JC, Guo, Y, Whiteley, WN et al.. Genetic associations of adult height with risk of cardioembolic and other subtypes of ischemic stroke: A mendelian randomization study in multiple ancestries. PLoS Med. 2022;19 (4):e1003967. doi: 10.1371/journal.pmed.1003967. PubMed PMID:35452448 PubMed Central PMC9032370.
  • Tapela, NM, Collister, J, Liu, X, Clifton, L, Stiby, A, Murgia, F et al.. Are polygenic risk scores for systolic blood pressure and LDL-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment?. Eur J Prev Cardiol. 2022;29 (6):925-937. doi: 10.1093/eurjpc/zwab192. PubMed PMID:34864974 .
Search PubMed